Meptazinol: Difference between revisions
Content deleted Content added
Anthonyhcole (talk | contribs) m Typo'. |
ed ref |
||
| Line 71: | Line 71: | ||
}} |
}} |
||
'''Meptazinol''' (trade name '''Meptid''') is an [[opioid]] [[analgesic]] developed by Wyeth in the 1970s<ref>US Patent 4197239</ref>. Indications for use in moderate to severe [[pain]], most commonly used to treat pain in [[obstetrics]] ([[childbirth]]). A partial [[mu opioid receptor|µ-opioid receptor]] [[agonist]], its mixed [[agonist]]/[[Receptor antagonist|antagonist]] activity affords it a lower risk of [[physical dependence|dependence]] and [[drug abuse|abuse]] than full µ [[agonist]]s like [[morphine]]. Meptazinol exhibits not only a short onset of action, but also a shorter duration of action relative to other [[opioid]]s such as [[morphine]], [[pentazocine]], or [[buprenorphine]].<ref name="Holmes 1985">Holmes B, Ward A |
'''Meptazinol''' (trade name '''Meptid''') is an [[opioid]] [[analgesic]] developed by Wyeth in the 1970s<ref>US Patent 4197239</ref>. Indications for use in moderate to severe [[pain]], most commonly used to treat pain in [[obstetrics]] ([[childbirth]]). A partial [[mu opioid receptor|µ-opioid receptor]] [[agonist]], its mixed [[agonist]]/[[Receptor antagonist|antagonist]] activity affords it a lower risk of [[physical dependence|dependence]] and [[drug abuse|abuse]] than full µ [[agonist]]s like [[morphine]]. Meptazinol exhibits not only a short onset of action, but also a shorter duration of action relative to other [[opioid]]s such as [[morphine]], [[pentazocine]], or [[buprenorphine]].<ref name="Holmes 1985">{{ cite journal | author = Holmes B, Ward A | title = Meptazinol. A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Efficacy | journal = Drugs | year = 1985 | volume = 30 | issue = 4 | pages = 285–312 | pmid = 2998723 }}</ref> |
||
==References== |
==References== |
||
Revision as of 03:17, 10 July 2012
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Dependence liability | Low |
| Routes of administration | Oral, IM, IV |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Metabolism | The peak analgesic effect is seen within 30–60 minutes and lasts about 3–4 hours. |
| Elimination half-life | Half-Life (1.4–4 hours). |
| Excretion | The drug is rapidly metabolised to the glucuronide, and mostly excreted in the urine. |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.053.718 |
| Chemical and physical data | |
| Formula | C15H23NO |
| Molar mass | 233.34922 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Meptazinol (trade name Meptid) is an opioid analgesic developed by Wyeth in the 1970s[1]. Indications for use in moderate to severe pain, most commonly used to treat pain in obstetrics (childbirth). A partial µ-opioid receptor agonist, its mixed agonist/antagonist activity affords it a lower risk of dependence and abuse than full µ agonists like morphine. Meptazinol exhibits not only a short onset of action, but also a shorter duration of action relative to other opioids such as morphine, pentazocine, or buprenorphine.[2]
References
External links
- Meptazinol at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
 | This analgesic-related article is a stub. You can help Wikipedia by expanding it. |